A study of "Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants". Chauvin et al

Published: 24 January 2023| Version 1 | DOI: 10.17632/krh7cy99wg.1
Contributors:
CAMILLE CHAUVIN,
LAURINE LEVILLAYER,
MATHILDE ROUMIER,
HUBERT NIELLY,
CLAUDE ROTH,
ANUPAMA KARNAM,
SRINIVASA REDDY BONAM,
ANNE BOURGARIT-DURAND,
CLEMENT DUBOST,
AURORE BOUSQUET,
SEBASTIEN LE BUREL,
RAPHAELE MESTIRI,
DAMIEN SENE,
JORIS GALLAND,
MARC VASSE,
MATHIEU GROH,
MATHILDE LE MARCHAND,
CAMILLE VASSORD-DANG,
Jean-Francois Gautier,
NHAN PHAM-THI,
CHRISTIANE VERNY,
BRUNO PITARD,
Cyril Planchais,
HUGO MOUQUET,
RICHARD PAUL,
ETIENNE SIMON-LORIERE,
jagadeesh Bayry,
LAURENT GILARDIN,
ANAVAJ SAKUNTABHAI

Description

Supplementary Dataset for the manuscript "Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants". Description of each patient according to disease severity and treatment. 55 out of 69 patients were recruited during the first COVID-19 wave while 14 patients were recruited during the second/third wave of COVID-19.

Files

Institutions

Institut Pasteur, INSERM, Sorbonne Universite, Universite de Paris

Categories

Patient, Interleukin-6, COVID-19

Funding

Agence Nationale de la Recherche

ANR-20-COVI-0093- COVIMUNE

License